Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.26 -0.47 (-3.69%) Market Cap: 538.00 Mil Enterprise Value: 484.06 Mil PE Ratio: 0 PB Ratio: 5.42 GF Score: 56/100

Q2 2020 Y-mAbs Therapeutics, Inc Earnings Call Transcript

Aug 07, 2020 / 01:00PM GMT
Release Date Price: $38.03 (-4.33%)
Operator;Thomas Gad
Y-mAbs Therapeutics, Inc. - Founder, Chairman, President & Head of Business Development and Strategy

Good morning, and welcome to the Y-mAbs Therapeutics, Inc. Second Quarter 2020 Earnings Conference Call. Today's conference is being recorded.

Let me quickly remind you that the following discussion contains certain statements that are considered forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Because forward-looking statements involve risks and uncertainties, they are not guarantees of future performance, and actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including those factors discussed in the company's annual report on Form 10-K for the fiscal year ended December 31, 2019, as well as with the SEC on March 12, 2020, and in the company's sequentially filed SEC reports.

At this time, I would like to turn the conference over to Mr. Thomas Gad, the company's Founder, Chairman and President. Please go ahead, sir.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot